Abstract. Transgenic expression of interleukin-6 (IL-6) in the CNS under the control of the glial fibrillary acidic protein (GFAP) gene promoter (GFAP-IL6 mice) causes significant damage and alters the expression of many genes, including a dramatic upregulation of metallothionein-I (MT-I). The findings in this report support the idea that the upregulation of MT-I observed in GFAP-IL6 mice is an important mechanism for coping with brain damage. Thus, GFAP-IL6 mice that were crossed with TgMTI transgenic mice (GFAP-IL6xTgMTI) and overexpressed MT-I in the brain showed a decreased upregulation of cytokines such as IL-6 and a diminished recruitment and activation of macrophages and T cells throughout the CNS but mainly in the cerebellum. The GFAP-IL6 mice showed clear evidence of increased oxidative stress, which was significantly decreased by MT-I overexpression. Interestingly, MT-I overexpression increased angiogenesis in GFAP-IL6 mice but not in control littermates. Overall, the results strongly suggest that MT-IϩII proteins are valuable factors that protect against cytokineinduced CNS injury.
INTRODUCTION
It is now clear that cytokines are essential mediators of cell-cell communication in the CNS, and that astrocytes, microglia, and macrophages are major sources of these proteins that profoundly affect glia and neuron physiology (1) (2) (3) (4) . While the cellular expression of cytokines in the CNS is very low in normal conditions, in a number of neuropathological conditions their expression may be dramatically altered (5, 6) . It is likely that such alterations could contribute to the clinicopathological features of many neurological disorders, and indeed results obtained in transgenic mice with astrocyte targeted expression of cytokines such as IL-6 (GFAP-IL6 mice) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) , IL-3 (15, (17) (18) (19) , IFN-␣ (15, (20) (21) (22) , TNF (23, 24) , and IL-12 (25) have demonstrated that an abnormal cytokine production may cause significant neurological disorder. On the other hand, these transgenic mice are useful animal models for the characterization of the mechanisms underlying cytokine-induced pathological conditions in the CNS, as well as for identifying potentially important genes for coping with CNS damage. One such family of genes is the metallothionein (MT) family, which we have thoroughly studied in the GFAP-IL6 mice. These transgenic mice show profound effects of IL-6 in the brain, with clear symptoms of neurodegeneration, astrocytosis, microgliosis, angiogenesis, and upregulation of several inflammatory and other host-response genes, including IL-1 ␣/␤, TNF, GFAP, ICAM-1, the acute-phase protein EB22/5, and complement C3 protein. Moreover, concordant with these structural alterations, GFAP-IL6 mice have impaired hippocampal electrophysiology and develop a progressive learning deficit.
MTs are cysteine-rich, heavy metal binding, low molecular weight proteins, which in rodents are comprised of 4 isoforms (MT-I to MT-IV) (26, 27) . In the brain only 3 isoforms are expressed, MT-I, MT-II, and MT-III (also known as growth inhibitory factor). MT-IϩII are widely expressed and regulated coordinately in most tissues including the CNS (28, 29) , while MT-III is mainly expressed in the CNS and shows a very different pattern of regulation compared to that of other MT isoforms (26) . MTs bind zinc and copper and presumably function in metal ion regulation and detoxification in peripheral tissues as well as in the CNS, while more recent evidence suggest that MTs could be significant antioxidant proteins (30) (31) (32) . In previous studies we have shown that MT-I mRNA and MT-IϩII protein levels are dramatically increased in the brains of the GFAP-IL6 mice (33, 34) , which presumably forms part of the physiological repertoire elicited in the brain for coping with tissue injury. To test this possibility, we recently crossed GFAP-IL6 mice with Mt1ϩ2-null mice and demonstrated that these proteins were important for coping with transgenic IL-6-induced CNS damage (35) . In this report we extend that study by crossing GFAP-IL6 mice with transgenic mice overexpressing MT-I (TgMTI) (36) , thus characterizing the effects of MT-I overexpression on the phenotype of GFAP-IL6 mice. The results fully support the hypothesis that MT-IϩII are essential proteins for coping with brain injury induced by cytokines such as IL-6.
MATERIALS AND METHODS

Animals
Homozygous TgMTI mice were kindly provided by Dr. Glen K. Andrews, Department of Biochemistry and Molecular Biology, University of Kansas Medical Center (Kansas City, KS). These mice were derived from heterozygous males that carry 56 copies of a minimally mutated Mt1 (Mt1*) gene on the B6/ SJL F 1 background (36), which were outbred to CD-1 females (37) . TgMTI mice are routinely genotyped by Southern blot as previously described (38) .
Construction and characterization of the GFAP-IL6 transgenic mice has been described previously (7) . Briefly, an expression vector derived from the murine glial fibrillary acidic protein (GFAP) gene was used to target expression of murine IL-6 to astrocytes. The GFAP-IL6 mice have a mixed C57B6xSJL genetic background, and are routinely genotyped by PCR as previously described (39) .
Production of GFAP-IL6-TgMTI Mice
For obtaining GFAP-IL6 mice with genetic MT-I overexpression and proper controls, we crossed homozygous TgMTI male mice with CD1 females. The offspring mice were all heterozygous for the 56 Mt1* genes and they were crossed with heterozygous GFAP-IL6 mice. The offspring of this second cross were genotyped by PCR (39) and Southern blot (38) for identifying 4 possible genotypes: (a) GFAP-IL6Ϯ TgMTIϮ, (b) GFAP-IL6Ϯ TgMTIϪ/Ϫ, (c) GFAP-IL6Ϫ/Ϫ TgMTIϮ, and (d) GFAP-IL6Ϫ/Ϫ TgMTIϪ/Ϫ. These F2 mice have the same genetic background and thus can be compared directly. This experimental design was followed in 2 separate experiments. Animals were studied at different ages (2-13 months old) and typically 5 to 10 animals per group were used.
In Situ Hybridization
The mice were killed and their brains removed, frozen in liquid nitrogen, and stored at Ϫ80ЊC. Later, serial coronal sections (20 m in thickness) were obtained with a cryostat and mounted on slides coated with poly(L)lysine. The in situ hybridization analysis of the MT-I and GFAP mRNAs was carried out as described previously (34) .
RNase Protection Assay
RNase protection assay for the detection of cytokine and host gene RNA was performed as described previously (8, 40, 41) . The intensity of the bands was measured densitometrically and normalized with the L32 mRNA levels.
Histochemistry and Immunohistochemistry
Animals were studied at 3 and 7 month of age and typically 5 to 10 animals per group were used. In some stainings, cell counts were carried out in a blinded manner in specific brain areas in 4 animals per group for statistical purposes. For tissue processing, the mice were perfused and sections prepared as previously described (35) .
Histochemistry: Sections were incubated overnight at 4ЊC with biotinylated tomato lectin from Lycopersicin esculentum (Sigma-Aldrich, St. Louis, MO) 1:500, which was used as a marker for cells of the myelo-monocytic cell lineages, such as microglia/macrophages, as well as a marker for vessels. The lectin was developed using streptavidin-biotin-peroxidase complex (StreptABComplex/HRP, Dako, Glostrup, Denmark) prepared according to the manufacturer's recommended dilutions for 30 min at room temperature. The lectin staining was visualized using 0.015% H 2 O 2 in 3,3-diaminobenzidine-tetrahydrochloride (DAB)/TBS for 10 min at room temperature. Hematoxylin and eosin (H&E) staining of brain sections was performed according to standard procedures.
Immunohistochemistry: The sections were incubated overnight at 4ЊC with one of the following antibodies. For detection of IL-6 and MT-IϩII, rat anti-mouse IL-6 1:50 (Harlan Seralab, Indianapolis, IN), and rabbit anti-rat MT-Iϩ2 1:500 (42) (43) (44) were used.
For detection of inflammatory cells and cytokines, rabbit anti-bovine GFAP 1:250 (Dako) as a marker for astrocytes, rat anti-mouse MOMA-2 1:50 (Serotec, Oxford, UK) marking only peripherally blood-derived monocytes/macrophages, mouse anti-rat CD3 1:50 (Serotec) as a marker for all T lymphocytes, mouse anti-human IL-1␤ 1:50 (Biogenesis, Kingston, NH), and rabbit anti-mouse TNF 1:100 (Biosource, Camarillo, CA) were used.
For detection of oxidative stress and apoptosis, rabbit antihuman iNOS 1:100 (Alexis Biochemicals, San Diego, CA) as a marker for oxidative stress, rabbit anti-NITT 1:100 (Alpha Diagnostic Int., San Antonio, TX) as a marker for peroxynitriteinduced nitration of tyrosine residues that monitors oxidative stress, rabbit anti-MDA 1:100 (Alpha Diagnostic Int.) as a marker for malondialdehyde (MDA) produced as a byproduct of fatty acid peroxidation, which monitors oxidative stress, mouse anti-human Cu/Zn-super oxide dismutase (Cu/Zn-SOD Two crossings (Exp. 1/2) were carried out as described in Materials and Methods. Mendelian distribution of the GFAP-IL6 and TgMTI transgenes is normal.
Fig. 1.
Representative in situ hybridization analysis for MT-I mRNA of the 4 genotypes studied at 13 months. TgMT-I mice showed dramatically increased MT-I mRNA levels throughout the CNS, although telencephalic areas showed a smaller increase. The transgenic expression of IL-6 upregulated MT-I expression in the cerebellum, while the combination of both transgenes tended to further increase MT-I mRNA levels (see Table 2 for quantitative measurements).
For detection of angiogenesis, rabbit anti-human VonWillebrand Factor 1:100 (Neomarkers, Fremont, CA), mouse anti-rat endothelial barrier antigen (EBA) 1:100 (Affinity, Nottingham, UK) as a marker of an endothelial blood-brain barrier antigen, goat anti-human angiopoietin-1/4 1:100 (Santa Cruz Biotechnology, Santa Cruz, CA) marking angiogenesis and vascular remodeling, rat anti-mouse perlecan 1:50 (Neomarkers) as a marker of angiogenesis and neovascularization, mouse antihuman CD34 1:30 (Neomarkers) marking proliferating vascular endothelial cells, mouse anti-human vascular endothelial growth factor (VEGF) 1:30 (R&D Systems, Minneapolis, MN), rabbit anti-human bFGF 1:100 (Santa Cruz Biotechnology), rabbit anti-human TGF-␤1 1:200 (Santa Cruz Biotechnology), and goat anti-human endoglin/TGF␤-receptorIII 1:100 (Santa Cruz Biotechnology) were used. The detection of these primary antibodies and the controls for specificity were performed essentially as described previously (35) .
Statistical Analysis
Results were analyzed with the Student t-test, the MannWhitney U-test, or with 2-way ANOVA.
RESULTS
The frequency of the offspring genotypes is normal. Table 1 shows the data for 2 separate series of crossings.
In general, it can be concluded that neither MT-I overexpression nor GFAP-IL6 expression, or the combination of both, had any effect on the development of the offspring since a normal Mendelian distribution of transgene genotypes was clearly observed, namely 25% for each of the 4 groups of F2 offspring: 1) GFAP-IL6Ϯ TgMTIϮ; 2) GFAP-IL6Ϯ TgMTIϪ/Ϫ; 3) GFAP-IL6Ϫ/Ϫ TgMTIϮ; and 4) GFAP-IL6Ϫ/Ϫ TgMTIϪ/Ϫ.
Clinical Characterization
The GFAP-IL6 mice showed clear symptoms of neurological damage, with hunched posture, tremor, ataxia, and hindlimb weakness, as expected (7). The mice were evaluated in some behavioral tests (hole-board, rota-rod, balance bar) but no statistical differences between genotypes were observed for locomotor activity (number of areas crossed in the hole-board) or coordination (rota-rod, balance bar), exploratory activity (head-dips and rearing in the hole-board), and emotionality (number of defecations in the hole-board). As expected, old GFAP-IL6 mice tended to weigh less than littermate controls (7), but no statistically significant effects of MT-I overexpression were observed (data not shown). In situ hybridization analysis for MT-I mRNA was carried out as described in Materials and Methods. All samples were processed in parallel and exposed to the same autoradiographic film. A representative section of each genotype is shown in Figure  1 . Results are arbitrary units, mean Ϯ SE. *** p Ͻ 0.001 vs respective GFAP-IL6Ϫ/Ϫ mice. ᭡p Ͻ 0.002 vs respective TgMTIϪ/Ϫ mice. Results (arbitrary units; mean Ϯ SE; n ϭ 4-7) were evaluated with 2-way ANOVA with GFAP-IL6 transgene and MT-I overexpression as main factors. When only 2 groups were compared, the Student t-test was employed. ND, not detectable. *** p Ͻ 0.001 vs respective GFAP-IL6Ϫ/Ϫ mice. ᭡p Ͻ 0.002 s TgMTIϪ/Ϫ mice.
MT-I mRNA and MT-IϩII Protein Levels Are Increased by Transgenic IL-6 and MT-I Expression
Confirming previous studies (33, 34) , the transgenic expression of IL-6 altered MT-I expression in a brain area-specific manner, with the cerebellum the area most affected ( Fig. 1; Table 2 ). MT-I mRNA levels in the cerebellum of TgMTIϪ/Ϫ mice were similarly upregulated by the transgenic IL-6 expression in 2-and 13-month-old animals. Also as expected (45), MT-I mRNA levels were significantly higher in the TgMTIϮ mice; we herewith report that MT-I mRNA levels increase significantly with aging (Table 3) . MT-I mRNA levels tended to be further increased in the GFAP-IL6Ϯ TgMTIϮ mice. Interestingly, MT-I mRNA levels of all the TgMTI mice were less upregulated in telencephalic areas than in the remaining brain.
MT-IϩII protein levels were also analyzed by immunohistochemistry (Fig. 2) . In GFAP-IL6Ϫ/Ϫ TgMTIϪ/Ϫ mice, MT-IϩII expression was seen in some astrocytes dispersed throughout the CNS as well as in meningeal cells, ependymal cells, and choroid plexus, while microglia, oligodendrocytes, and neurons appeared devoid of MT-IϩII expression. Confirming the above results, MT-IϩII immunoreactivity was significantly increased by the transgenic IL-6 expression throughout the brain but especially in the cerebellum. Also as expected, MT-IϩII immunoreactivity was dramatically increased in the GFAPIL6Ϫ/Ϫ TgMTϮ mice. The highest levels of MT-IϩII immunoreactivity were seen in the GFAP-IL6Ϯ TgMTIϮ mice. Bergmann glia, astrocytes, and microglia/ macrophages were the main cellular sources of MT-IϩII in the cerebellum of GFAPIL6Ϯ TgMTIϪ/Ϫ and GFAP-IL6Ϫ/Ϫ TgMTIϮ mice, but the latter showed some staining also in endothelial cells and in a few neurons.
In other brain areas such as the forebrain and the brainstem of the GFAP-IL6Ϯ TgMTIϪ/Ϫ and GFAP-IL6Ϫ/Ϫ TgMTIϮ mice, astrocytes and microglia/macrophages were the main cells that expressed MT-IϩII, but again the latter mice showed some MT-IϩII staining in some endothelial cells and a few neurons (not shown).
MT-I Overexpression Decreases GFAP-IL6-Induced
Cytokine Expression 3 . Analysis of cytokine gene expression. mRNA levels of a number of cytokines in the cerebellum of 7-month-old mice were measured by RNase protection assay. The sample labeled with a star belongs to the GFAP-IL6Ϯ TgMTIϮ group. As expected, some cytokines were upregulated in those animals with transgenic expression of IL-6, namely TNF, IL-1␣, IL-6, and IL-1␤. MT-I overexpression decreased this upregulation as shown by the densitometric analysis of the bands and normalization with the L32 ribosomal mRNA (see Table 3 ).
TgMTIϮ mice, IL-6 immunoreactivity was only seen in the meninges, while intraparenchymal cells of the CNS were negative. In the GFAP-IL6Ϯ TgMTIϪ/Ϫ mice, IL-6 immunoreactivity increased throughout the CNS but especially in the cerebellum. IL-6 immunoreactivity was mainly seen in Bergmann glia, round or amoeboid microglia/macrophages, and in some astrocytes and a few T cells of the cerebellum white and grey matter. In the forebrain and brainstem, IL-6 immunoreactivity was only detected in some scattered astrocytes (not shown). IL-6 immunoreactivity was significantly lower in GFAP-IL6Ϯ TgMTIϮ than in GFAP-IL6Ϯ TgMTIϪ/Ϫ mice, suggesting that MT-I overexpression decreased IL-6 expression. This effect was also seen in the forebrain and brainstem (not shown).
To confirm the immunohistochemistry data, IL-6 mRNA levels were measured in the cerebellum of 7 month-old animals by a specific ribonuclease protection assay that measures a number of cytokines simultaneously (Fig. 3) . Densitometric quantitation and normalization of the cytokine mRNA with the L32 mRNA levels demonstrated that MT-I overexpression decreased GFAP-IL6-induced IL-6 expression significantly (Table 3) , in accordance with the immunohistochemistry results. IL-1␣, IL-1␤, and TNF expression was clearly increased in the GFAP-IL6 mice, although to a lower extent than that of IL-6 (Table 3) . MT-I overexpression tended to decrease such responses, although statistical significance was not achieved for any of these 3 cytokines. Overall the same results were observed for IL-1␤ and TNF protein levels as detected by immunohistochemistry (not shown). Lectin immunoreactivity in the cerebellum from 7-month-old mice. In GFAP-IL6Ϫ/Ϫ TgMTIϪ/Ϫ mice, lectin staining was mainly seen in vessels but also in a very few ramified microglial cells in cerebellum, both in the white (small star) and grey matter (large star). Transgenic IL-6 expression caused a significant activation of microglia/macrophages, especially in white matter. This response was dramatically blunted by MT-I overexpression. Scale bars ϭ 44 m.
MT-I Overexpression Decreases Microglia/Macrophage and T Lymphocyte Recruitment and Activation
CNS areas of GFAP-IL6Ϫ/Ϫ TgMTIϪ/Ϫ mice, lectin staining was seen in vessels and in a very few ramified microglial cells, while round macrophages were rare. Lectin staining in the GFAPIL6Ϯ TgMTIϪ/Ϫ mice showed that round macrophages and activated microglia heavily infiltrated the cerebellum mainly in the white matter. In the brainstem, only some activated microglia were seen around vessels in the GFAPIL6Ϯ TgMTIϪ/Ϫ mice, while the cerebral cortex of these mice only showed a few microglia/macrophage cells (not shown). MT-I overexpression was without effect on lectin staining in GFAP-IL6Ϫ/Ϫ mice, but it dramatically decreased the recruitment and activation of microglia/macrophages induced by IL-6 throughout the CNS judging by number of cells and morphology. The data obtained using lectin histochemistry was confirmed when using the macrophage marker MOMA-2. In accordance with the lectin staining, Mac1 mRNA levels were higher in GFAP-IL6 mice, and MT-I overexpression tended to decrease this ( Fig. 5; Table 3 ).
MT-I Overexpresssion Decreases T Lymphocyte
Recruitment and Activation T cells were detected by examining immunoreactivity for CD3. In the GFAP-IL6Ϫ/Ϫ TgMTIϪ/Ϫ mice, T lymphocytes were rarely detected throughout the CNS. In contrast, the GFAPIL6Ϯ TgMTIϪ/Ϫ mice showed recruitment of CD3ϩ cells, mainly to the cerebellum, which displayed many T lymphocytes around the vessels in white matter. In brainstem and forebrain of these mice, the number of recruited T cells was low. The GFAPIL6Ϫ/ Ϫ TgMTϮ mice showed immunoreactivity for CD3 that was comparable to that of GFAPIL6Ϫ/Ϫ TgMTϪ/Ϫ mice. The GFAPIL6Ϯ TgMTϮ mice showed clearly reduced numbers of T cells relative to the GFAPIL6Ϯ TgMTϪ/Ϫ mice, which indicated that MT reduced T cell recruitment by IL-6 (data not shown).
MT-I Overexpression Alters Astrocyte/Bergmann
Glia Reactivity GFAP immunostaining of the GFAP-IL6Ϫ/Ϫ Tg-MTIϪ/Ϫ mice showed a faint staining throughout the CNS (Fig. 6) . In GFAP-IL6Ϯ TgMTIϪ/Ϫ mice, GFAP staining increased progressively with age (not shown), and at 7 months of age reactive astrogliosis was obvious, especially in the Purkinje and molecular layers and in white matter of the cerebellum (Fig. 6 ), and to a lesser extent in brainstem and cortex (not shown).
Somewhat surprisingly, GFAP immunoreactivity was increased in 7-month-old GFAP-IL6Ϫ/Ϫ TgMTIϮ mice throughout the CNS (Fig. 6 ) compared with 3-month-old animals (not shown). In the cerebellum of 7-month-old GFAP-IL6Ϫ/Ϫ TgMTIϮ mice, most of the GFAP staining was seen in the Purkinje and molecular layers. This was in sharp contrast to GFAP-IL6Ϯ TgMTIϪ/Ϫ mice, which in addition to these 2 layers showed a significant reactive astrocytosis in the white matter. Overall, the transgenic IL-6 expression seemed to increase GFAP Analyses of host-response gene expression. Cerebellum mRNA levels of several host-response genes in 7-month-old mice were analyzed by RNase protection assay. The sample labeled with a star belongs to the GFAP-IL6Ϯ TgMTIϮ group. As expected, ICAM-I, Mac1, EB22/5, and GFAP expression was significantly increased in those animals with transgenic expression of IL-6. MT-I overexpression did not significantly alter any of the genes analyzed, although tended to decrease Mac1 and GFAP upregulation (Table 3) . A representative in situ hybridization analysis of GFAP mRNA in the 4 genotypes studied at 13 months of age is shown in the insert. In accordance with the RPA, the transgenic expression of IL-6 upregulated GFAP expression, which occurred mainly in the cerebellum. MT-I overexpression did not alter significantly GFAP mRNA levels, in agreement with the RPA results but in sharp contrast with the GFAP immunoreactivity results. The GFAP-IL6Ϯ TgMTIϮ mice had a similar GFAP expression to that of the GFAP-IL6Ϯ TgMTIϪ/Ϫ mice.
staining of the cerebellum to a greater extent than the MT-I overexpression, at least at the ages studied. In contrast, in the remaining brain areas the GFAP-IL6Ϫ/Ϫ TgMTIϮ mice showed significantly higher GFAP staining than GFAP-IL6Ϯ TgMTIϪ/Ϫ mice (not shown). GFAP-IL6Ϯ TgMTIϮ mice tended to have a greater GFAP immunoreactivity than either GFAP-IL6Ϯ Tg-MTIϪ/Ϫ or GFAP-IL6Ϫ/Ϫ TgMTIϮ mice, especially in the cerebellum (Fig. 6) and brainstem (not shown).
GFAP mRNA levels were also measured by RPA and in situ hybridization ( Fig. 5; Table 4 ). As expected, GFAP-IL6 mice showed a dramatic increase of GFAP mRNA levels in the cerebellum. In contrast to GFAP immunoreactivity, MT-I overexpression did not affect GFAP mRNA levels. The reasons for such discrepancies between GFAP mRNA and protein are unknown and deserve further attention.
MT-I Overexpression Decreases Oxidative Stress
In nontransgenic littermate animals, MDA (not shown) and NITT immunoreactivity was barely detectable in the CNS (Fig. 7) . In contrast, in GFAP-IL6Ϯ TgMTIϪ/Ϫ mice, MDA and NITT staining was clearly increased in the CNS, particularly in the cerebellum. These markers of oxidative stress were also significantly decreased in GFAP-IL6Ϯ TgMTIϮ mice at all ages studied. Both oxidative stress markers were detected mainly in neuronal cells but also in some astrocytes and microglia/macrophages. . GFAP immunoreactivity in cerebellum from 7-month-old mice. Significant reactive astrogliosis was observed in the white and grey matter of the cerebellum of the GFAP-IL6Ϯ TgMTIϪ/Ϫ mice. In some of the GFAP-IL6Ϫ/Ϫ TgMTIϮ mice, reactive astrogliosis could be observed throughout the CNS at this age; this was not seen in 3-month-old mice. In contrast to the mice with transgenic expression of IL-6, the GFAP immunostaining of the cerebellum was mainly observed in the molecular layer. In the GFAP-IL6Ϯ TgMTIϮ mice, the cerebellum showed a slightly increased GFAP staining relative to both the GFAP-IL6Ϯ TgMTIϪ/Ϫ and GFAP-IL6Ϫ/Ϫ TgMTIϮ mice. Scale bars ϭ 29 m.
MT-I Overexpression Increases Angiogenesis in GFAP-IL6 Mice but not in Control Littermates
H&E stainings of the cerebellum of the different genotypes studied (not shown) revealed the expected granular layer disorganization and increased angiogenesis caused by the transgenic expression of IL-6 (7, 13) . Figure 8 shows angiopoietin staining as a marker of angiogenesis, which showed an obvious increased angiogenesis in the GFAP-IL6Ϯ mice, in accordance with the H&E stainings. While not having any observable effect in GFAP-IL6Ϫ/Ϫ animals, MT-I overexpression significantly increased angiogenesis in GFAP-IL6Ϯ mice. These results were further supported by immunostaining for VEGF, VonWillebrand Factor, EBA (endothelial barrier antigen), perlecan, CD34, bFGF, TGF-␤1, and endoglin/ TGF␤-receptorIII (not shown), all supporting a proangiogenic effect of MT-IϩII during IL-6 induced CNS injury.
DISCUSSION
In a recent study, we analyzed the phenotype of GFAP-IL6 mice made deficient for MT-IϩII (35) . Here we have extended that study by generating GFAP-IL6 mice with MT-I overexpression to verify if an excess of MT-I can have the opposite effects to those caused by MT-IϩII deficiency. Overall, the results demonstrated that such upregulation is important in terms of tissue protection, presumably by controlling the inflammatory response and oxidative stress in the brain.
In line with previous observations, the GFAP-IL6 mice showed clear symptoms of neurological damage, with hunched posture, tremor, ataxia, and hindlimb weakness (7) . The previously reported histopathological features were also clearly observed, namely, neurodegeneration, microgliosis, astrocytosis, oxidative stress, angiogenesis, and upregulation of several inflammatory and other hostresponse genes, including IL-1 ␣/␤, TNF, GFAP, ICAM-1, and the acute-phase protein EB22/5. The cerebellum was the most affected area (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . In the present study we showed that GFAP-IL6 mice with MT-I overexpression have a significantly decreased inflammatory response in the brain, especially in the cerebellum. Thus, the recruitment and activation of macrophages and T cells, the production of inflammatory cytokines such as IL-6, IL-1␣,␤, and TNF, as well as oxidative stress were all lower in GFAP-IL6 mice with MT-I overexpression compared with littermate controls. Reactive astrocytosis, in contrast, showed the opposite response. Thus, GFAP-IL6 mice with MT-I overexpression showed a reversed pattern of responses for all the variables analyzed compared with those with MT-IϩII deficiency (35) . Overall, the results strongly support the idea that MT-IϩII are important proteins for coping with cytokine-induced CNS damage. Similar conclusions have been obtained from studies with animals subjected to cryolesion (39, (44) (45) (46) , experimental autoimmune encephalomyelitis (47) (48) (49) , convulsions (50), or mild focal cerebral ischemia (51) . MT-IϩII deficiency has also been shown to increase degenerative pathology in a mouse model of familial amyotrophic lateral sclerosis (52) .
Altogether, these results suggest that MT-IϩII are involved in the control of the inflammatory response in the CNS, although the mechanisms underlying this control are uncertain. A number of studies suggest that these proteins act at different levels of the immune system. First, binding sites for MT-IϩII have been described in T cells, B cells, and macrophages (53, 54) , and it is essential to realize that despite the absence of the typical signal peptide sequences in the Mt genes, extracellular MT-IϩII presence and response to factors such as stress and inflammation have been well documented (55) (56) (57) (58) . Second, exogenous MTs are able to induce lymphocyte proliferation (54, 59, 60) , although this cannot be considered a general effect, since the same group has reported that MTs decrease lymphocyte proliferation mediated by macrophage activity (53) . Third, MTs potentiate the capacity of macrophages to produce increased levels of oxygen radicals and to kill engulfed yeast cells (53) . In agreement with this study, decreased levels of oxygen radicals in response to LPS were observed in MT-depleted THP-1 cells (a human monocyte-derived cell line) (61) . Fourth, MTs have been found to inhibit significantly humoral responses to specific antigens (62) , as well as cytotoxic T lymphocyte activity (60) . Finally, it is noteworthy that results obtained with MT immunoneutralization using the UC1MT monoclonal antibody (62, 63) , as well those obtained in Mt1ϩ2-null mice (64), support a role for MT in the control of the humoral immune response, but conflicting results regarding the role of MTs on the lymphoproliferative response are obvious (64, 65) . Other recent studies add more controversy to the interaction between MTs and the immune system. Kimura et al reported that Mt1ϩ2-null mice were more sensitive to LPS/GalN-induced lethality, suggesting a protective role of MTs (66) . This has been confirmed (67), yet these authors report that Mt1ϩ2-null mice are protected against TNF-induced shock while MT-I overexpressing mice are sensitized, suggesting a deleterious role for MTs. It seems clear that MTs could affect cell proliferation, differentiation, and function separately, and that depending on the specific insult activating the immune system, quite different physiological outcomes might occur.
Regardless of the mechanisms involved, it is clear that MT-IϩII have the potential to dramatically decrease the inflammatory response in the CNS, as demonstrated in the present study. The decreased macrophage and T cell infiltration of the CNS of animals with astrocyte-targeted expression of IL-6 caused by MT-I overexpression, together with the downregulation of several proinflammatory cytokines and the increased astrogliosis would undoubtedly contribute to the control of oxidative stress, since these cells are key factors controlling free radical production, antioxidant mechanisms, and apoptosis pathways (3, (68) (69) (70) (71) . It is also likely that MT-IϩII are important as antioxidant and antiapoptotic factors (29, (72) (73) (74) (75) (76) (77) (78) (79) (80) .
It is also noteworthy that the present results support an important role of MT-IϩII in the control of angiogenesis in the injured CNS. We previously demonstrated a decreased angiogenesis in cryolesioned Mt1ϩ2-null mice (39) and the reverse phenomenon in MT-I overexpressing mice (45) . Such a proangiogenic role of MT-IϩII is not observed in unlesioned animals, which suggests that these proteins interact specifically with tissue injury-elicited factors. In a very different animal model of CNS injury, GFAP-IL6 mice, we have now demonstrated that MT-I overexpression also seems to promote angiogenesis. These mice appeared to have a higher number of vessels, with a higher percentage enlarged in comparison to those of GFP-IL6Ϯ TgMTIϪ/Ϫ. Although a more quantitative approach to precisely determine the extent of the increased vessel density is desirable in future studies, we did also note here that the angiogenic factor angiopoietin-1/4 (as well as VEGF, VonWillebrand Factor, EBA, perlecan, CD34, bFGF, TGF-␤1, and endoglin/TGF␤-receptorIII) was also consistently increased. These findings are replicated in both models of CNS injury, namely the cryolesion and the astrocyte targeted IL-6 expression, and thus it is likely that they might be underlying the MT-IϩII-related angiogenic effects (39) . Importantly, GFAP-IL6 mice with MT-IϩII deficiency show decreased angiogenesis (35) , in accordance with the above results.
In summary, the present results provide a rationale for the control of the Mt1ϩ2 genes by IL-6 in the CNS, and demonstrate that these proteins are likely important factors for coping with cytokine-induced CNS injury.
